High efficacy of therapeutic equine hyperimmune antibodies against SARS CoV-2 variants of concern
Moreira-Soto, A.; Arguedas, M.; Brenes, H.; Bujan, W.; Corrales-Aguilar, E.; Diaz, C.; Echeverri, A.; Flores-Diaz, M.; Gomez, A.; Hernandez, A.; Herrera, M.; Leon, G.; Macaya, R.; Khüne, A.; Molina-Mora, J. A.; Mora, J.; Sanabria, A.; Sanchez, A.; Sanchez, L.; Segura, A.; Segura, E.; Solano, D.; Soto, C.; Stynoski, J. L.; Vargas, M.; Villalta, M.; Reusken, C.; Drosten, C.; Gutierrez, J. M.; Alape-Giron, A.; Drexler, J. F.
Show abstract
SARS-CoV-2 variants of concern (VoC) show reduced neutralization by vaccine-induced and therapeutic monoclonal antibodies. We tested therapeutic equine polyclonal antibodies (pAbs) against four VoC (alpha, beta, epsilon and gamma). We show that equine pAbs efficiently neutralize VoC, suggesting they are an effective, broad coverage, low-cost and a scalable COVID-19 treatment.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Susceptibility of raccoon dogs for experimental SARS-CoV-2 infection 92%
- Novel Hendra virus variant detected by sentinel surveillance of Australian horses. 92%
- Respiratory shedding of infectious SARS-CoV-2 Omicron XBB.1.41.1 lineage with increased evolutionary rate among captive white-tailed deer 91%
Similar papers in this journal
- AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans 93%
- SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster 92%
- The effect of anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, on endogenous immune response to COVID-19 vaccination 91%
Similar papers in this journal
- SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates Against Symptomatic Infection 92%
- The comparability of Anti-Spike SARS-CoV-2 antibody tests is time-dependent: a prospective observational study 91%
- The impact of early anti-SARS-CoV-2 antibody production on the length of hospitalization stay among COVID-19 patients 91%
Similar papers in this journal
- Validation and clinical evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) 92%
- Live virus neutralisation testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2 91%
- An ACE2 decamer viral trap as a durable intervention solution for current and future SARS-CoV 91%
Similar papers in this journal
- NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge 93%
- Safety and Immunogenicity of An Egg-Based Inactivated Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomized, Placebo-Controlled, Phase 1/2 Trial in Vietnam 93%
- An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits potent immunity after a single dose. 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.